The award-winning Startup Inveox is insolvent. The reason for this is a financial crisis triggered by a sudden lack of financing from its shareholders. The Munich District Court has granted the insolvency application and appointed attorney Marc-André Kuhne as provisional insolvency administrator. Kuhne has already initiated a structured investor process in cooperation with the M&A consulting firm Falkensteg. The goal is to Company and to preserve as many of the 20 jobs as possible.
Since 2017, Inveox has been working on improving the processing of tissue samples, especially for cancer diagnostics, through innovative technology. software The health tech company digitizes sample shipment and receipt in the laboratory. A smart sample container and an automatic Sample processing system are intended to make the entire process safer, faster, and less error-prone. The core idea is to automate and digitize tissue sample processing and enable AI-assisted diagnostics.
According to the company, over 100 histopathology laboratories in Germany were involved in the development of the concept. The device is currently being installed and commissioned in a private clinic. Further investments are required before it is finally ready for market.
"Inveox's technology is highly innovative, and there is undoubtedly a market need for digitizing pathology laboratory processes. Therefore, I am optimistic that we will find a long-term and stable continuation solution for this very exciting company,"
explains lawyer Kuhne, provisional insolvency administrator from the law firm Dkr Kuhne Dr. Raith in Munich.
Numerous awards for Inveox
Inveox was named Startup of the Year by Forbes in 2018. In the same year, the healthtech also won the Munich Startup AwardIn 2019, the company was a finalist for the German Innovation Award, and in 2020 it was honored by the Ministry of Economic Affairs as Digital Startup of the Year.
Founders also Dominik Sievert is sure:
"Our technology has proven itself, and we see strong customer interest in a market that urgently demands digitalization and increased efficiency. We've already proven that our system works."
Co-founder Maria Sievert adds:
"Our mission is to make cancer diagnostics safer and faster. The urgent need for digitalization and automation in pathology is obvious."
